Literature DB >> 3153013

Growth from birth to adulthood in a patient with the neonatal form of Bartter syndrome.

W Proesmans1, G Massa, M Vanderschueren-Lodeweyckx.   

Abstract

Growth from birth to the age of 19 years was studied in a patient with the neonatal form of Bartter syndrome. The initial modes of therapy (extra fluid, potassium supplements and triamterene) resulted in satisfactory but not optimal growth. Treatment with spironolactone together with potassium led to impressive catch-up growth. When the patient reached the age of 9 years, indomethacin therapy was started, which resulted in a second growth acceleration and was also accompanied by a significant reduction of both polyuria and hypercalciuria. Puberty developed normally, menarche occurred at 12 years 4 months and a normal adult height of 162 cm was reached at the age of 14 years. Treatment with prostaglandin synthetase inhibitors seems to be the best therapy for children with the neonatal form of Bartter syndrome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3153013     DOI: 10.1007/bf00862592

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

1.  Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome.

Authors:  F C BARTTER; P PRONOVE; J R GILL; R C MACCARDLE
Journal:  Am J Med       Date:  1962-12       Impact factor: 4.965

2.  Bartter's syndrome. Differentiation into two clinical groups.

Authors:  W L Robson; G S Arbus; J W Balfe
Journal:  Am J Dis Child       Date:  1979-06

3.  Effect of ibuprofen on growth in a child with Bartter syndrome.

Authors:  G Lechacz; G S Arbus; J W Balfe; E D Wolff; L Robson
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

4.  A sibship with Bartter's syndrome: failure of total adrenalectomy to correct the potassium wasting.

Authors:  C W Trygstad; J A Mangos; J M Bloodworth; C C Lobeck
Journal:  Pediatrics       Date:  1969-08       Impact factor: 7.124

Review 5.  Juxtaglomerular cell hyperplasia and secondary hyperaldosteronism (Bartter's syndrome): a re-evaluation of the pathophysiology.

Authors:  P J Cannon; J M Leeming; S C Sommers; R W Winters; J H Laragh
Journal:  Medicine (Baltimore)       Date:  1968-03       Impact factor: 1.889

6.  Direct radioimmunoassay of plasma aldosterone in normal subjects.

Authors:  P Lijnen; A Amery; R Fagard; P Corvol
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

7.  Neonatal Bartter's syndrome, indomethacin and necrotising enterocolitis.

Authors:  N Marlow; M L Chiswick
Journal:  Acta Paediatr Scand       Date:  1982-11

8.  Bartter syndrome. Typical facies and normal plasma volume.

Authors:  T James; N H Holland; D Preston
Journal:  Am J Dis Child       Date:  1975-10

9.  Bartter's syndrome presenting with features resembling renal tubular acidosis. Improvement of renal tubular defects by indomethacin.

Authors:  J Rodriguez-Soriano; A Vallo; R Oliveros
Journal:  Helv Paediatr Acta       Date:  1978-06

10.  Fetal polyuria and hydramnios associated with Bartter's syndrome.

Authors:  U V Sieck; A Ohlsson
Journal:  Obstet Gynecol       Date:  1984-03       Impact factor: 7.661

View more
  7 in total

1.  Female ROMK null mice manifest more severe Bartter II phenotype on renal function and higher PGE2 production.

Authors:  Qingshang Yan; Xinbo Yang; Alessandra Cantone; Gerhard Giebisch; Steven Hebert; Tong Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-06-25       Impact factor: 3.619

2.  Acetyl salicylic acid treatment in neonatal Bartter syndrome.

Authors:  Suna Serife Oğuz; Tülin Gökmen; Omer Erdeve; Nurdan Uras; Ugur Dilmen
Journal:  Pediatr Nephrol       Date:  2011-05-10       Impact factor: 3.714

3.  Gitelman's syndrome is genetically distinct from other forms of Bartter's syndrome.

Authors:  L Károlyi; A Ziegler; M Pollak; M Fischbach; K H Grzeschik; M C Koch; H W Seyberth
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  Pre-pubertal growth in the hyperprostaglandin E syndrome.

Authors:  C Seidel; S Reinalter; H W Seyberth; K Schärer
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

5.  Dose related growth response to indometacin in Gitelman syndrome.

Authors:  L C Liaw; K Banerjee; M G Coulthard
Journal:  Arch Dis Child       Date:  1999-12       Impact factor: 3.791

6.  Neonatal Bartter syndrome.

Authors:  Mamta N Muranjan; Vishakha C Kantharia; S B Bavdekar; Ujjwala Kabde; Ramesh C Parmar
Journal:  Indian J Pediatr       Date:  2002-01       Impact factor: 1.967

Review 7.  Prostanoids in paediatric kidney diseases.

Authors:  H W Seyberth; A Leonhardt; B Tönshoff; N Gordjani
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.